Literature DB >> 11408242

In vitro activities of four novel triazoles against Scedosporium spp.

A J Carrillo1, J Guarro.   

Abstract

In order to develop new approaches to the treatment of the severe and usually fatal infections caused by Scedosporium spp., the in vitro antifungal activities of four novel triazoles (posaconazole, ravuconazole, voriconazole, and UR-9825) and some current antifungals (amphotericin B, ketoconazole, itraconazole, and nystatin) were determined. The latter group was clearly ineffective against the two species tested. The four new antifungals showed activity against Scedosporium apiospermum, and UR-9825 and voriconazole were active against S. prolificans.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11408242      PMCID： PMC90619          DOI： 10.1128/AAC.45.7.2151-2153.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

Authors:  J Berenguer; J L Rodríguez-Tudela; C Richard; M Alvarez; M A Sanz; L Gaztelurrutia; J Ayats; J V Martinez-Suarez
Journal:  Medicine (Baltimore)       Date:  1997-07       Impact factor: 1.889

2.  Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.

Authors:  P Muñoz; M Marín; P Tornero; P Martín Rabadán; M Rodríguez-Creixéms; E Bouza
Journal:  Clin Infect Dis       Date:  2000-12       Impact factor: 9.079

3.  In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

Authors:  J Meletiadis; J W Mouton; J L Rodriguez-Tudela; J F Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease.

Authors:  N Jabado; J L Casanova; E Haddad; F Dulieu; J C Fournet; B Dupont; A Fischer; C Hennequin; S Blanche
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

5.  Cerebral pseudallescheriasis due to Pseudallescheria boydii as the first manifestation of AIDS.

Authors:  A Montero; J E Cohen; M A Fernández; G Mazzolini; C R Gómez; J Perugini
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

6.  New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.

Authors:  J Bartroli; E Turmo; M Algueró; E Boncompte; M L Vericat; L Conte; J Ramis; M Merlos; J García-Rafanell; J Forn
Journal:  J Med Chem       Date:  1998-05-21       Impact factor: 7.446

7.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi.

Authors:  I Pujol; J Guarro; C Llop; L Soler; J Fernández-Ballart
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.

Authors:  G Ramos; M Cuenca-Estrella; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

9.  Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis.

Authors:  T S Tadros; K A Workowski; R J Siegel; S Hunter; D A Schwartz
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

10.  Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii.

Authors:  T J Walsh; J Peter; D A McGough; A W Fothergill; M G Rinaldi; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191
View more
  43 in total

Review 1.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

2.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

5.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

Authors:  M Simitsopoulou; C Gil-Lamaignere; N Avramidis; A Maloukou; S Lekkas; E Havlova; L Kourounaki; D Loebenberg; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  Disposition of posaconazole following single-dose oral administration in healthy subjects.

Authors:  Philip Krieter; Brian Flannery; Timothy Musick; Mark Gohdes; Monika Martinho; Rachel Courtney
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.